Cargando…
Gaps in Evidence‐Based Therapy Use in Insured Patients in the United States With Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease
BACKGROUND: Evidence‐based therapies are generally underused for cardiovascular risk reduction; however, less is known about contemporary patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease. METHODS AND RESULTS: Pharmacy and medical claims data from within Anthem were q...
Autores principales: | Nelson, Adam J., Ardissino, Maddalena, Haynes, Kevin, Shambhu, Sonali, Eapen, Zubin J., McGuire, Darren K., Carnicelli, Anthony, Lopes, Renato D., Green, Jennifer B., O’Brien, Emily C., Pagidipati, Neha J., Granger, Christopher B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955303/ https://www.ncbi.nlm.nih.gov/pubmed/33432843 http://dx.doi.org/10.1161/JAHA.120.016835 |
Ejemplares similares
-
Use of Lipid-, Blood Pressure–, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
por: Nelson, Adam J., et al.
Publicado: (2022) -
Current approach to the diagnosis of atherosclerotic coronary artery disease: more questions than answers
por: Nelson, Adam J., et al.
Publicado: (2019) -
One-Year Adverse Outcomes Among US Adults With Post–COVID-19 Condition vs Those Without COVID-19 in a Large Commercial Insurance Database
por: DeVries, Andrea, et al.
Publicado: (2023) -
Characterization of bariatric surgery and outcomes using administrative claims data in the research network of a nationwide commercial health plan
por: Ma, Qinli, et al.
Publicado: (2021) -
A Rapid and Sensitive Method to Measure the Functional Activity of Shiga Toxins in Human Serum
por: Arfilli, Valentina, et al.
Publicado: (2015)